Drug profile · INN
daratumumab
DARZALEX
daratumumab (DARZALEX) is a lymphocyte differentiation antigen cd38 inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — daratumumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 50
- Data quality
- 0.84
Quick answer
daratumumab (DARZALEX) is a lymphocyte differentiation antigen cd38 inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Lymphocyte differentiation antigen CD38 inhibitor
Primary target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is daratumumab?
daratumumab (DARZALEX) is a lymphocyte differentiation antigen cd38 inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for daratumumab?
DARZALEX is a marketed brand name for daratumumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daratumumab?
daratumumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.